DOCSLIB.ORG

Roche Annual Report 2006

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Roche Annual Report 2006 Roche Annual Report 2006 Part 2 Finance Report We Innovate Healthcare Innovation spanning the entire healthcare spectrum As a pharmaceuticals and a diagnostics company, Roche brings pioneering products and services to market for every stage of the healthcare process, from identifying disease susceptibilities and testing for disease in at-risk populations to prevention, diagnosis, therapy and treatment monitoring. Our focus on products that deliver significant benefits to patients and health professionals is a core element of our business strategy, and one of the key reasons for our success. As a research-intensive company with a long-term strategic focus, Roche strives to deliver sustainable value to all stakeholders. Table of Contents Finance Report 2006 Roche Group 2 Finance in brief 2 Finance – 2006 in brief 3 Financial Review 4 Operating results 4 Non-operating results 13 Cash flows and net cash 15 Balance sheet 16 Pensions and other post- employment benefits 17 Roche securities 18 Financial risks 19 International Financial Reporting Standards 21 Roche Group Consolidated Financial Statements 22 Income statement 22 Balance sheet 24 Cash flow statement 25 Statement of recognised income and expense 26 Statement of changes in equity 27 Notes to the Roche Group Consolidated Financial Statements 28 Report of the Group Auditors 97 Multi-Year Overview 98 Supplementary Net Income and EPS Information 101 Roche Securities 102 Roche Holding Ltd, Basel 104 Financial Statements 104 Income statement 104 Balance sheet 105 Notes to the Financial Statements 106 Appropriation of Available Earnings 108 Report of the Statutory Auditors 109 Finance Report 2006 1 Finance in brief Key results Operating profit margin before exceptional items, Local sales growth % % of sales Pharmaceuticals 2006 +21.3 31.7 2005 +24.8 27.6 Diagnostics 2006 +4.7 16.3 2005 +4.2 21.5 Group 2006 +17.4 27.9 2005 +19.3 25.9 2006 2005 % change % of sales (mCHF) (mCHF) (CHF) (LC) 2006 2005 Sales 42,041 35,511 +18 +17 EBITDA1) 14,436 11,568 +25 +24 34.3 32.6 Operating profit before exceptional items 11,730 9,189 +28 +27 27.9 25.9 Profit from continuing businesses before exceptional items 9,151 7,099 +29 21.8 20.0 Net income 9,171 6,866 +34 21.8 19.3 Net cash 16,088 11,215 +43 Equity 46,814 40,158 +17 Equity ratio 62.9% 58.0% Core EPS2) in CHF 9.86 7.84 +26 Dividend per share3) in CHF 3.40 2.50 +36 1) EBITDA: Earnings before exceptional items and before financial income, financing costs, tax, depreciation and amortisation, including impairment. This corresponds to operating profit before exceptional items and before depreciation and amortisation, including impairment. 2) See page 101 for definition of Core EPS. 3) Proposed by the Board of Directors. LC = local currencies. Finance Executive Team Erich Hunziker Chief Financial Officer Hubert Buck Management Development Peter Eisenring Taxes and Insurances Marco Frei Pension Asset Management Andreas Knierzinger Treasury Steve Krognes Corporate Development Karl Mahler Investor Relations Erwin Schneider Accounting and Controlling 2 Finance Report 2006 Finance – 2006 in brief Sales • Group sales grew by 17% in local currencies to 42.0 billion Swiss francs, driven primarily by the fast organic growth of the Pharmaceuticals Division. • Pharmaceuticals sales increased by 21% in local currencies or 6.0 billion Swiss francs, strongly outperforming the global market thanks to the key oncology products and also Tamiflu, Bonviva/Boniva and Lucentis. Pharmaceuticals sales now account for 79% of Group sales. • Oncology product sales grew by 37% in local currencies to 15.3 billion Swiss francs, representing 46% of pharmaceuticals sales. • Diagnostics sales increased by 5% in local currencies to 8.7 billion Swiss francs, driven primarily by the Centralized Diagnostics business. Operating results • Operating profit (before exceptional items) increased by 27% in local currencies to 11.7 billion Swiss francs based on the strong business growth and continuing productivity improvements. • Record profitability, with operating profit margin (before exceptional items) up by 2.0 percentage points to 27.9%. • R&D expenditure increased by 16% in local currencies to 6.6 billion Swiss francs, representing 16% of Group sales. • Significant investment in new biotechnology manufacturing facilities. Treasury • Increase in net financial income to 855 million Swiss francs, compared to 328 million Swiss francs in 2005. • Partial redemption of ‘LYONs V’ convertible notes and further repayment of bank debt reduces debt by 1.4 billion Swiss francs. Financial condition • Increase in net cash to 16.1 billion Swiss francs from 11.2 billion Swiss francs. • Increase in equity ratio to 63% from 58%. • Decrease in debt-equity ratio to 18% from 24%. • Aa1 rating by Moody’s and AA+ rating by Standard & Poor’s maintained. Net income • Increase in overall net income of 34% to 9.2 billion Swiss francs, primarily from the strong operating performance. Shareholder return • Market capitalisation increased by 12% to 192 billion Swiss francs. Share price up by 13%, price of non-voting equity security up by 11%. • Increase in Core EPS of 26% to 9.86 Swiss francs, outpacing Swiss franc sales growth by 8 percentage points. • Increase in proposed dividend of 36% to 3.40 Swiss francs, representing the 20th consecutive year of dividend growth. Finance Report 2006 3 Roche Group Financial Review Operating results Group operating results Sales Operating profit (before exceptional items) in billions of CHF % LC growth in billions of CHF % of sales 2006 +17.4 27.9 2005 +19.3 25.9 20041) +11.8 22.9 0 10 20 30400 246810 12 1) Continuing businesses. The 2006 annual results once again show a strong operating performance both in terms of top-line sales growth as well as profit margins, mainly driven by the Pharmaceuticals Division. Total sales grew by 17% in local currencies (18% in Swiss francs; 18% in US dollars) to 42.0 billion Swiss francs, with the Pharmaceuticals Division contributing 79% of Group sales and the Diagnostics Division representing 21%. The incremental sales increase of 6.5 billion Swiss francs was achieved through organic growth and primarily driven by strong demand for the Group’s oncology drugs Herceptin, Avastin, MabThera/Rituxan and Tarceva, by the anti-influenza drug Tamiflu, and by Bonviva/Boniva and Lucentis. This sales increase is after absorbing over 500 million Swiss francs of lower Rocephin sales globally following the product’s US patent expiry in July 2005. The Group’s operating profit before exceptional items increased by 27% in local currencies to 11.7 billion Swiss francs and the corresponding operating profit margin grew by 2.0 percentage points to 27.9%. This was driven by an increase in Pharmaceuticals of 4.1 percentage points which more than offset a decline in the margin in Diagnostics of 5.2 percentage points. This overall margin growth was achieved at the same time as the Group continued to increase investments in the strong development pipeline and in launch and pre-launch activities. The exchange rate impact on sales and operating profit growth as expressed in Swiss francs was moderate, with Swiss-franc growth being 0 to 1 percentage point higher than local-currency growth. In 2006, the average exchange rate for the US dollar was 1% higher and the euro was 2% higher, while the Japanese yen lost 5%. 4 Finance Report 2006 Roche Group Financial Review Group operating results 2006 Pharmaceuticals Diagnostics Corporate Group (mCHF) (mCHF) (mCHF) (mCHF) Sales 33,294 8,747 – 42,041 Operating profit before exceptional items 10,545 1,422 (237) 11,730 – margin 31.7 16.3 – 27.9 EBITDA 12,168 2,500 (232) 14,436 – margin 36.5 28.6 – 34.3 Group operating results – Development of results compared to 2005 Pharmaceuticals Diagnostics Corporate Group Sales – % increase in local currencies +21 +5 – +17 Operating profit before exceptional items – % increase in local currencies +40 –21 +96 +27 – margin: percentage point increase +4.1 –5.2 – +2.0 EBITDA – % increase in local currencies +34 –5 +99 +24 – margin: percentage point increase +3.2 –3.1 – +1.7 Pharmaceuticals operating results The Pharmaceuticals Division showed a strong sales increase, with growth of 21% in local currencies (22% in Swiss francs; 21% in US dollars) to 33.3 billion Swiss francs, outpacing growth in the global market by a factor of more than three. Operating profit before exceptional items was 10.5 billion Swiss francs, representing a growth of 40% in local currencies. Consequently there was a further margin increase of 4.1 percentage points to 31.7%. Marketing and distribution costs significantly increased by 17% in local currencies to 8.8 billion Swiss francs reflecting the support for recently launched on-market products and pre-launch activities for global rollouts and new indications. R&D investment in the pipeline continued with 5.9 billion Swiss francs of expenditure, an increase of 19% in local currencies. Pharmaceuticals Division results 2006 2005 % change % change (mCHF) (mCHF) (CHF) (local currencies) Sales 33,294 27,268 +22 +21 Royalties and other operating income 1,277 1,176 +9 +8 Cost of sales (6,868) (6,016) +14 +11 Marketing and distribution (8,761) (7,458) +17 +17 Research and development (5,889) (4,970) +18 +19 General and administration (1,849) (1,785) +4 +3 Amortisation and impairment of intangible assets (659) (676) –3 –3 Operating profit before exceptional items 10,545 7,539 +40 +40 – margin 31.7 27.6 +4.1 EBITDA 12,168 9,073 +34 +34 – margin 36.5 33.3 +3.2 Sales: The major growth drivers were the oncology, transplantation and virology franchises (including Tamiflu), with the key oncology franchise again significantly outpacing the market.
Load more

Recommended publications
  • Fund Holdings
    Wilmington International Fund as of 7/31/2021 (Portfolio composition is subject to change) ISSUER NAME % OF ASSETS ISHARES MSCI CANADA ETF 3.48% TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD 2.61% DREYFUS GOVT CASH MGMT-I 1.83% SAMSUNG ELECTRONICS CO LTD 1.79% SPDR S&P GLOBAL NATURAL RESOURCES ETF 1.67% MSCI INDIA FUTURE SEP21 1.58% TENCENT HOLDINGS LTD 1.39% ASML HOLDING NV 1.29% DSV PANALPINA A/S 0.99% HDFC BANK LTD 0.86% AIA GROUP LTD 0.86% ALIBABA GROUP HOLDING LTD 0.82% TECHTRONIC INDUSTRIES CO LTD 0.79% JAMES HARDIE INDUSTRIES PLC 0.78% DREYFUS GOVT CASH MGMT-I 0.75% INFINEON TECHNOLOGIES AG 0.74% SIKA AG 0.72% NOVO NORDISK A/S 0.71% BHP GROUP LTD 0.69% PARTNERS GROUP HOLDING AG 0.65% NAVER CORP 0.61% HUTCHMED CHINA LTD 0.59% LVMH MOET HENNESSY LOUIS VUITTON SE 0.59% TOYOTA MOTOR CORP 0.59% HEXAGON AB 0.57% SAP SE 0.57% SK MATERIALS CO LTD 0.55% MEDIATEK INC 0.55% ADIDAS AG 0.54% ZALANDO SE 0.54% RIO TINTO LTD 0.52% MERIDA INDUSTRY CO LTD 0.52% HITACHI LTD 0.51% CSL LTD 0.51% SONY GROUP CORP 0.50% ATLAS COPCO AB 0.49% DASSAULT SYSTEMES SE 0.49% OVERSEA-CHINESE BANKING CORP LTD 0.49% KINGSPAN GROUP PLC 0.48% L'OREAL SA 0.48% ASSA ABLOY AB 0.46% JD.COM INC 0.46% RESMED INC 0.44% COLOPLAST A/S 0.44% CRODA INTERNATIONAL PLC 0.41% AUSTRALIA & NEW ZEALAND BANKING GROUP LTD 0.41% STRAUMANN HOLDING AG 0.41% AMBU A/S 0.40% LG CHEM LTD 0.40% LVMH MOET HENNESSY LOUIS VUITTON SE 0.39% SOFTBANK GROUP CORP 0.39% NOVARTIS AG 0.38% HONDA MOTOR CO LTD 0.37% TOMRA SYSTEMS ASA 0.37% IMCD NV 0.37% HONG KONG EXCHANGES & CLEARING LTD 0.36% AGC INC 0.36% ADYEN
    [Show full text]
  • Alcon-20-F-2020.Pdf
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring the shell company report __________ Commission file number: 001-31269 Alcon Inc. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant's name into English) Switzerland (Jurisdiction of incorporation or organization) Rue Louis-d'Affry 6, 1701 Fribourg, Switzerland (Address of principal executive office) Royce Bedward, Chemin de Blandonnet 8, 1214 Vernier, Geneva, Switzerland; Tel: +41 58 911 20 00; Fax +41 58 911 32 22 (Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act. Title of each class Trading Symbol(s) Name of each exchange on which registered SIX Swiss Exchange Ordinary Shares, nominal value CHF 0.04 per share ALC New York Stock Exchange Securities registered or to be registered pursuant to Section 12(g) of the Act. None Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.
    [Show full text]
  • Corporate Governance Report
    Corporate Governance Report 30 June 2009 Board of Directors Executive Board Contents Preliminary remarks 3 1. Board of Directors 4 1.1 Members of the Board of Directors 4 1.2 Professional background and other activities and functions 4 1.3 Cross-involvement 7 1.4 Internal organisational structure 8 2. Executive Board 10 2.1 Members of the Executive Board 10 2.2 Professional background and other activities and functions 11 General Organisation of Nestlé S.A. 15 Situation at 30 June 2009 © 2009, Nestlé S.A., Cham and Vevey (Switzerland) Concept Nestlé S.A., Group Governance Design Nestec Ltd., SGDU, Corporate Identity & Design 2 Nestlé Corporate Governance Report June 2009 Preliminary remarks Nestlé S.A. publishes a full Corporate Governance Report, Contact for Media: including a separate Compensation Report, which Nestlé S.A. forms an integral part of the annual Management Report. Corporate Media Relations We therewith comply with the requirements of the Avenue Nestlé 55 SIX Swiss Exchange (SIX) and its Corporate Governance CH - 1800 Vevey (Switzerland) Directive. tel. +41 (0)21 924 22 00 The present document is a partial update of the fax +41 (0)21 922 63 34 Nestlé Corporate Governance Report 2008, indicating e-mail: [email protected] changes occurred on the Board of Directors and the Executive Board up to 30 June 2009. Contact for Investors: The annual Management Report is available Nestlé S.A. on-line as a PDF file at http://www.nestle.com in English, Investor Relations French and German. Copies can be ordered at: Avenue Nestlé 55 http://www.nestle.com/Media_Center/Order.
    [Show full text]
  • Annual Report 2015
    Annual Report 2015 — Financial Overview Annual Report 2015 Financial Overview Corporate Governance Report Remuneration Report Report Financial Annual Report 2015 Financial Overview Financial Report Remuneration Report Corporate Governance Report Financial Report Remuneration Report Consolidated Financial Statements Compensation and Performance Overview 2015 100 Consolidated Balance Sheet 4 Compensation-Setting Process 101 Consolidated Income Statement 5 Compensation Components 103 Consolidated Statement of Comprehensive Income 5 Compensation of the Board of Directors 104 Consolidated Cash Flow Statement 6 Compensation of the Executive Committee 106 Consolidated Statement of Changes in Equity 7 Share Ownership of the Members of the Board of Notes to the Consolidated Financial Statements 8 Directors and the Executive Committee 116 Report of the Statutory Auditor 81 Report of the Statutory Auditor 119 Financial Statements of Lonza Group Ltd, Basel Balance Sheet 82 Corporate Governance Report Income Statement 83 Notes to the Financial Statements 84 Group Structure and Shareholders 122 Proposal of the Board of Directors 89 Capital Structure 124 Report of the Statutory Auditor 91 Board of Directors 127 Executive Committee 139 Supplementary Financial Information Compensation, Shareholdings and Loans 143 Investor Information 92 Shareholders’ Participation Rights 143 Statement of Value Added 94 Changes of Control and Defense Measures 144 Free Cash Flow 95 Auditors 145 CORE Results 96 Information Policy and Key Reporting Dates 146 Financial Report
    [Show full text]
  • Supreme Court of the United States
    No. 03-724 IN THE Supreme Court of the United States ———— F. HOFFMANN-LA ROCHE LTD, HOFFMANN-LA ROCHE INC., ROCHE VITAMINS INC., BASF AG, BASF CORP., RHÔNE-POULENC ANIMAL NUTRITION INC., RHÔNE-POULENC INC., et al., Petitioners, v. EMPAGRAN, S.A., et al., Respondents. ———— On Writ of Certiorari to the United States Court of Appeals for the District of Columbia Circuit ———— JOINT APPENDIX ———— ARTHUR F. GOLDEN MICHAEL D. HAUSFELD Counsel of Record Counsel of Record DAVIS POLK & WARDWELL COHEN, MILSTEIN, HAUSFELD 450 Lexington Avenue & TOLL, P.L.L.C. New York, NY 10017 1100 New York Ave., N.W. (212) 450-4000 Washington, D.C. 20005 (202) 408-4600 Attorneys for Petitioner F. Hoffmann-La Roche Ltd Attorneys for Respondents [Names and addresses of additional counsel listed on signature pages of parties’ briefs] PETITION FOR CERTIORARI FILED NOVEMBER 13, 2003 PETITION FOR CERTIORARI GRANTED DECEMBER 15, 2003 TABLE OF CONTENTS Page Chronological List of Relevant Docket Entries............. 1 Notice of Designation of Related Civil Cases Pending In This Or In Any Other United States Court, dated July 17, 2000.............................................................. 3 Plaintiffs’ Amended Class Action Complaint, dated November 14, 2000 ................................................... 6 Order of the United States District Court for the District of Columbia, dated June 7, 2001 .................. 69 ii TABLE OF CONTENTS—Continued Page The following opinions, judgments and orders have been omitted in printing this joint appendix because they appear on the following pages of the appendix to the Petition for Certiorari: Memorandum Opinion of the United States District Court for the District of Columbia, dated June 7, 2001 ..........................................................................
    [Show full text]
  • Annual Report 2016 Corporate Governance Report Segments Financial Report Company Remuneration Report
    Corporate Annual Report 2016 Company Segments Financial Corporate Report Governance Report Remuneration Report Contact us Corporate inquiries and further information, please contact: Global Headquarters Lonza Group Ltd Muenchensteinerstrasse 38 4002 Basel, Switzerland Tel +41 61 316 81 11 Fax +41 61 316 91 11 www.lonza.com Investor Relations Tel +41 61 316 85 40 Fax +41 61 316 95 40 [email protected] Media / Corporate Communications Tel +41 61 316 87 98 Fax +41 61 316 97 98 [email protected] Share Register c/o Computershare Schweiz AG P.O. Box 4601 Olten, Switzerland Tel +41 62 205 7700 Fax +41 62 205 7790 [email protected] Production Details Production Corporate Communications, Lonza Group Ltd, Basel (CH) All rights reserved Design and Illustration Lonza Design Team Website and Programming Lonza Digital Team Photography Gregor Brändli, Basel (CH) with thanks to the Natural History Museum Basel Company Letter to Shareholders Lonza at a Glance Financial Highlights 2016 Governance Management and Company Structure Investor Information Delivering on Our Strategy Sustainable Values Lonza Annual Report 2016 1 Letter to Shareholders Dear Fellow Shareholders, Last year’s record performance was not just a “one­off” result as it represented the fifth year in a row that we delivered improvements on all major financial performance indicators. Since we started our transformational journey in late 2012, we have shown steady and continued improvement in all our key performance indicators, which in turn has been reflected in significant improvements in our share price. We are grateful to you, our shareholders, for the faith you have demonstrated in Lonza with your ownership.
    [Show full text]
  • Schedule of Investments International Equity Portfolio^ (Unaudited) September 30, 2020
    Schedule of Investments International Equity Portfolio^ (Unaudited) September 30, 2020 NUMBER OF NUMBER OF SHARES VALUE SHARES VALUE 108,300 Sanwa Holdings Corp. $ 1,148,343 Common Stocks 96.9% 11,400 SCSK Corp. 637,818 Austria 1.2% (a) 9,400 Shionogi & Co. Ltd. 503,128 25,905 BAWAG Group AG $ 936,585 8,700 TechnoPro Holdings, Inc. 544,720 Belgium 0.7% 17,700 Terumo Corp. 704,720 11,337 KBC Group NV 568,506 15,100 Tokio Marine Holdings, Inc. 660,694 Canada 0.8% 16,100 Toyota Motor Corp. 1,068,557 4,458 Kinaxis, Inc. 656,237* 8,971,615 China 1.2% Luxembourg 0.4% 25,272 Alibaba Group Holding Ltd. 927,763* 7,570 Befesa SA 303,705(a) France 7.3% Netherlands 6.6% 3,942 Air Liquide SA 624,845 4,488 ASML Holding NV 1,657,746 (b) 3,372 Arkema SA 357,514 11,265 Heineken NV 1,002,887 (a) 8,232 Pernod-Ricard SA 1,312,476 28,494 Intertrust NV 485,031 * 8,941 Schneider Electric SE 1,111,356 23,067 Koninklijke Philips NV 1,089,203 5,393 Teleperformance 1,662,672 7,280 NXP Semiconductors NV 908,617 (b) 16,748 TOTAL SE 575,169 5,143,484 5,644,032 Norway 0.7% *(a) Germany 11.4% 73,154 Sbanken ASA 528,710 * 2,683 adidas AG 866,453 Singapore 0.8% 16,232 Brenntag AG 1,032,060 * 44,000 DBS Group Holdings Ltd. 646,859 14,354 CTS Eventim AG & Co.
    [Show full text]
  • LONZA FINANCE INTERNATIONAL NV (Incorporated in Belgium As a Société Anonyme/Naamloze Vennootschap)
    LONZA FINANCE INTERNATIONAL NV (incorporated in Belgium as a société anonyme/naamloze vennootschap) €500,000,000 1.625 per cent. Guaranteed Bonds due 2027 guaranteed by Lonza Group AG (a stock corporation organised under Swiss law) Issue Price: 99.424 per cent. The €500,000,000 1.625 per cent. Guaranteed Bonds due 2027 (the “Bonds”) will be issued by Lonza Finance International NV (the “Issuer”) and guaranteed by Lonza Group AG (the “Guarantor”). Interest on the Bonds will be payable annually in arrear on 21 April in each year, commencing on 21 April 2021. Payments on the Bonds will be made without deduction for or on account of taxes of the Kingdom of Belgium or Switzerland to the extent described under “Terms and Conditions of the Bonds — Taxation”. The Bonds will mature on 21 April 2027 (the “Maturity Date”). The Bonds will be subject to redemption in whole, but not in part at their principal amount, together with accrued interest, at the option of the Issuer (a) during the period between 90 days prior to the Maturity Date (the “Early Call Date”) and the Maturity Date; (b) at any time if 80 per cent. or more in principal amount of the Bonds originally issued have been redeemed (other than where 80 per cent. or more in principal amount of the Bonds originally issued have been redeemed pursuant to the Issuer Make Whole Call Option) or purchased; and (c) at any time in the event of certain changes affecting taxation in the Kingdom of Belgium or Switzerland. The Bonds will also be subject to redemption in whole or in part at the higher of (a) their principal amount or (b) the sum of the then present values of the remaining scheduled payments of principal and interest discounted to the Make Whole Optional Redemption Date (as defined herein) on an annual basis and assuming, for this purpose, that the Bonds are to be redeemed on the date falling 90 days prior to the Maturity Date, in each case together with accrued interest, at the option of the Issuer at any time.
    [Show full text]
  • For a Resilient Future
    For a resilient future 2016 Financial Report Financial highlights Our Group delivered a good net income of USD 3.6 billion, supported by all Business Units. Financial highlights For the years ended 31 December USD millions, unless otherwise stated 2015 2016 Change in % Group Net income attributable to common shareholders 4 597 3 5 5 8 –23 Premiums earned and fee income 30 214 33 231 10 Earnings per share in CHF 12.93 10.55 –18 Common shareholders’ equity 32 415 3 4 5 3 2 7 Return on equity in %1 13.7 10.6 Return on investments in % 3.5 3.4 Net operating margin in %2 17.1 13.0 Number of employees3 12 767 14 0 5 3 10 Property & Casualty Reinsurance Net income attributable to common shareholders4 3 0 08 2 10 0 –30 Premiums earned 15 090 17 0 0 8 13 Combined ratio in %2,4 85.7 93.5 Net operating margin in %2,4 22.5 15.4 Return on equity in %1,4 22.4 16.4 Life & Health Reinsurance Net income attributable to common shareholders4,5 968 807 –17 Premiums earned and fee income5 10 616 11 5 2 7 9 Net operating margin in %2,4,5 12.2 10.4 Return on equity in %1,4,5 16.2 12.8 Corporate Solutions Net income attributable to common shareholders4 357 135 –62 Premiums earned 3 379 3 5 0 3 4 Combined ratio in %4 93.2 101.1 Net operating margin in %4 14.1 4.2 Return on equity in %1,4 15.5 6.0 Life Capital Net income attributable to common shareholders4,5 424 638 50 Premiums earned and fee income5 1 129 1 19 3 6 Gross cash generation6 543 721 33 Net operating margin in %4,5 17.8 27.0 Return on equity in %1,4,5 7.5 10.4 1 Return on equity is calculated by dividing net income attributable to common shareholders by average common shareholders’ equity.
    [Show full text]
  • Full-Year Results 2020 Pierre-Alain Ruffieux, CEO Rodolfo Savitzky, CFO
    Full-Year Results 2020 Pierre-Alain Ruffieux, CEO Rodolfo Savitzky, CFO 27 January 2021 Hong Kong Aerial scene in night, with road and traffic 1 Contents Full-Year 2020 Corporate Overview Full-Year 2020 Financial Summary Lonza Segments: • Pharma Biotech & Nutrition (LPBN) • Specialty Ingredients (LSI) Outlook 2021 and Mid-Term Guidance 2023 Q&A Appendices Urban crowd from above 2 Full-Year 2020 Corporate Overview Aerial view of Independence monument in Mexico City 3 Full-Year 2020 Corporate Overview Strong full-year performance, driven by sales growth in LPBN Lonza delivers on guidance1 with 12.0%2 sales growth, with CHF 4.5 billion sales, and CHF 1.4 billion CORE EBITDA, resulting in a 31.2% margin Lonza results mainly reflect Pharma Biotech & Nutrition (LPBN) performance, as Specialty Ingredients (LSI) is reported as a discontinued operation Strong performance in LPBN with 12.2%2 sales growth and CORE EBITDA margin of 32.1%, driven by Biologics business Production of the drug substance for Moderna COVID-19 Vaccine has commenced at Portsmouth (USA) and Visp (CH) sites LSI3 delivered a solid performance, with 3.4%2 sales growth alongside an improved CORE EBITDA margin, reported at 20.3%4 Winding road at Faroe 1 2020 Guidance relates to Lonza Group results without LSI reported as discontinued operations 2 All sales growth figures are at a constant exchange rate (CER) 3 Specialty Ingredients Business (excluding Corporate/carve-out and divestiture costs directly attributable to LSI) CORE definition: See appendix 4 4 CORE EBITDA margin at
    [Show full text]
  • Fund Risk Management
    FUND RISK MANAGEMENT Monthly Report Umbrella Cosmos Lux International Net Asset Value 10,401,340.66 Sub-fund CHF Currency CHF May 2017 Portfolio date 29/05/2017 FUND ID Fund name Cosmos Lux International TNA end of period 10,401,340.66 NAV end of period 119.34 Sub-fund name CHF TNA start of period 9,945,879.95 NAV start of period 114.11 ISIN LU0989373237 TNA Variation 4.58% NAV Variation 4.58% Currency CHF Benchmark SWISS MARKET INDEX Subscriptions 0.00 FUND RISK PROFILE Low Redemptions 0.00 RISK MANAGEMENT COMMENTS Stale price overview No stale price. Operational risk No material NAV error occurred during the period. No massive redemption occurred during the period. Risk Metrics: Scorecard reporting 4Cs (based on NAV date) Leverage Counterparty risk Concentration risk Liquidity risk . <100% NAV <5% or 10% <10% >90% liquid day Investment Compliance dashboard There are no Breaches to display. Investment Compliance specific NA Total Expense Ratio - Internal limit 3% As of 31/03/2017 (quarterly): Without transaction fees B CAP 2.48% Portfolio Turnover As of 31/03/2017 (quarterly): 12.67% VaR - Leverage NA Liquidity Risk No issue to report. Investment Manager comments 1 FUND RISK MANAGEMENT Monthly Report Umbrella Cosmos Lux International Net Asset Value 10,401,340.66 Sub-fund CHF Currency CHF May 2017 Portfolio date 29/05/2017 Regulatory main limit checks Check result Indicator Check result Indicator Issuer Exposure < 10% NAV 6.32% Cash Counterparty Exposure < 20% NAV 2.59% OECD Govt Bond Exposure < 35% NAV 6.13% OTC Counterparty Exposure NA 5/40 Rule 33.25% Aggregated Group Exposure 6.32% Borrowing limit < 10% NAV NA Cover Rule (liquid assets vs.
    [Show full text]
  • News Release
    News release Swiss Re reports good results, with full-year net income of USD 3.6 billion for 2016; proposes new share buy-back • Group net income of USD 3.6 billion, supported by continued Media Relations, solid underwriting performance and strong investment result Zurich Telephone +41 43 285 7171 • Property & Casualty Reinsurance net income USD 2.1 billion; ROE of 16.4% New York Telephone +1 914 828 6511 • Life & Health Reinsurance net income USD 807 million; ROE of 12.8% Hong Kong Telephone +852 2582 3660 • Corporate Solutions net income USD 135 million; ROE of 6.0% • Life Capital net income USD 638 million; gross cash generation Investor Relations, of USD 721 million and ROE of 10.4% Zurich Telephone +41 43 285 4444 • Continued strong investment performance in challenging yield environment; ROI 3.4% Swiss Re Ltd Mythenquai 50/60 • Capacity reduction due to disciplined underwriting in most P.O. Box segments lead to premium volume decrease in January 2017 CH-8022 Zurich renewals; price quality exceeds hurdle rate • Board of Directors to propose a rise in regular dividend to Telephone +41 43 285 2121 Fax +41 43 285 2999 CHF 4.85 per share and the authorisation of a new public share buy-back programme of up to CHF 1.0 billion www.swissre.com • Swiss Re proposes to elect Jay Ralph and Joerg Reinhardt to the @SwissRe Board of Directors • Matthias Weber to step down as Group Chief Underwriting Officer; Edouard Schmid to succeed him Zurich, 23 February 2017 – Swiss Re delivers a good 2016 performance with full-year net income of USD 3.6 billion, supported by solid underwriting and a strong investment result.
    [Show full text]